Actively Recruiting
Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer
Led by City of Hope Medical Center · Updated on 2025-07-11
150
Participants Needed
1
Research Sites
402 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Although advances in chemotherapy have improved the prognosis of gastric cancer patients, many patients still suffer from adverse events. Therefore, it is necessary to establish personalized treatment by identifying patients at high risk for side effects. Although paclitaxel-based therapy is the standard second-line treatment, peripheral neuropathy is a troublesome adverse event. The purpose of this study is to establish a liquid biopsy assay to predict paclitaxel-induced peripheral neuropathy in gastric cancer patients.
CONDITIONS
Official Title
Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- unresectable or recurrent Gastric cancer (GC) histologically confirmed to be primary adenocarcinoma of the stomach.
- age over 20 years.
- Eastern Cooperative Oncology Group performance status score of 0-2.
- written informed consent following full study information is provided to the patient.
- progression or intolerance for first-line chemotherapy comprising fluorinated pyrimidine and platinum anticancer drugs (cisplatin or oxaliplatin) for advanced GC.
- presence of evaluable lesions as confirmed using a computed tomography (CT) or magnetic resonance imaging.
You will not qualify if you...
- Patients with a life expectancy of shorter than 3 months
- Patients with severe complications (angina pectoris, myocardial infarction, or arrhythmia) or uncontrollable diabetes mellitus, blood hypertension, or bleeding tendency.
- Patients with a history of serious allergic reactions or serious drug allergy.
- Patients with a clinically relevant mental disorder that prohibits response to questionnaires.
- Patients for whom the attending physician considered that enrollment in the study is inappropriate.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kawasaki Medical University
Kurashiki, Okayama-ken, Japan, 7010192
Actively Recruiting
Research Team
A
Ajay Goel, PhD
CONTACT
K
Koichi Takiguchi, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here